- Notification that Quarterly Report will be submitted late (NT 10-Q)
18 Mayo 2010 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
|
|
|
|
|
(Check one):
|
|
o
Form 10-K
o
Form 20-F
o
Form 11-K
o
Form 10-Q
þ
Form N-SAR
o
Form N-CSR
|
|
|
|
|
|
|
|
|
For Period Ended:
|
March
31, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 10-K
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 20-F
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 11-K
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 10-Q
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form N-SAR
|
|
|
|
|
|
|
|
|
|
For the Transition Period Ended:
|
|
|
|
|
|
|
|
|
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which
the notification relates:
PART I REGISTRANT INFORMATION
Escalon Medical Corp.
Full Name of Registrant
Former Name if Applicable
435 Devon Park Drive, Building 100
Address of Principal Executive Office
(Street and Number)
Wayne, PA 19087
City, State and Zip Code
PART II RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant
seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if
appropriate)
|
|
|
|
|
|
þ
|
|
|
(a)
|
|
The reason described in reasonable detail in Part III of
this form could not be eliminated without unreasonable
effort or expense
|
|
|
|
|
|
|
(b)
|
|
The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or
Form N-CSR, or portion thereof, will be filed on or
before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report or
transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filed on
or before the fifth calendar day following the prescribed
due date; and
|
|
|
|
|
|
|
|
(c)
|
|
The accountants statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
|
PART III NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the
transition report or portion thereof, could not be filed within the prescribed time period.(Attach
extra Sheets if Needed)
NARRATIVE
Escalon Medical Corp. (the Company) will not be able to file its report on Form 10-Q for the
period ended March 31, 2010 within the prescribed time period without unreasonable effort and
expense. The Company intends to file its Form 10-Q within the 5-day extension period afforded by
SEC Rule 12b-25 under the Securities Exchange Act of 1934, as amended.
Additional time is required to compile and analyze the financial records related to the
operations of subsidiaries of Company for the period ended March 31, 2010.
PART IV OTHER INFORMATION
(1)
|
|
Name and telephone number of person to contact
in regard to this notification
|
|
|
|
|
|
Robert OConnor
|
|
610
|
|
688-6830
|
|
|
|
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2)
|
|
Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or
for such shorter period that the registrant was required to file
such report(s) been filed? If answer is no, identify report(s).
|
Yes
þ
No
o
(3)
|
|
Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in
the subject report or portion thereof?
|
Yes
o
No
þ
|
|
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
|
Escalon Medical Corporation
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
Date May 18, 2010
|
|
By
|
|
/s/ Richard J. DePiano, Sr., CEO
|
|
|
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person signing the form shall be typed or
printed beneath the signature. If the statement is signed on behalf of the registrant by an
authorized representative (other than an executive officer), evidence of the representatives
authority to sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal
Criminal Violations (See 18 U.S.C.
1001).
GENERAL INSTRUCTIONS
1.
|
|
This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the
General Rules and Regulations under the Securities Exchange Act of
1934.
|
|
2.
|
|
One signed original and four conformed copies of this form and
amendments thereto must be completed and filed with the Securities
and Exchange Commission, Washington, D.C. 20549, in accordance
with Rule 0-3 of the General Rules and Regulations under the Act.
The information contained in or filed with the form will be made a
matter of public record in the Commission files.
|
|
3.
|
|
A manually signed copy of the form and amendments thereto shall be
filed with each national securities exchange on which any class of
securities of the registrant is registered.
|
|
4.
|
|
Amendments to the notifications must also be filed on Form 12b-25
but need not restate information that has been correctly
furnished. The form shall be clearly identified as an amended
notification.
|
|
5.
|
|
Electronic Filers:
This form shall not be used by electronic
filers unable to timely file a report solely due to electronic
difficulties. Filers unable to submit reports within the time
period prescribed due to difficulties in electronic filing should
comply with either Rule 201 or Rule 202 of Regulation S-T
(§232.201 or §232.202 of this chapter) or apply for an adjustment
in filing date pursuant to Rule 13(b) of Regulation S-T
(§232.13(b) of this chapter).
|
Escalon Medical (QB) (USOTC:ESMC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Escalon Medical (QB) (USOTC:ESMC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024